Home/Pipeline/BTQ1902

BTQ1902

Glaucoma

Phase 2Active

Key Facts

Indication

Glaucoma

Phase

Phase 2

Status

Active

Company

Betaliq

About Betaliq

Betaliq is a privately held, clinical-stage biotech focused on developing novel ophthalmic therapies for glaucoma using the exclusive EyeSol® technology. Its lead program, BTQ1902 (a timolol suspension), has completed a positive Phase 2a trial and is preparing for Phase 3. The company operates with a virtual model, is backed by an $8M Series A, and aims to address significant unmet needs in glaucoma care through improved drug delivery.

View full company profile

Therapeutic Areas

Ophthalmology Glaucoma

Other Glaucoma Drugs

Drug	Company	Phase	Status
PREZIA Glaucoma Implant	PolyActiva	Preclinical	Active
MIGS Device System	Micropoint Biotechnologies	Commercial	Market approved in China
INM-088	InMed Pharmaceuticals	Preclinical	Active
OT-401	Ocumension Therapeutics	Phase 2	Active
ANX007	Annexon Biosciences	Phase 2	Active
PER-001	Perfuse Therapeutics	Phase 2	Active
hOTX2	BrainEver	Discovery	Active
Glaucoma Treatment	BVI Medical	Commercial	Active
MediPrint Lens (Glaucoma)	MediPrint Ophthalmics	Phase 2b	Active
Glaucoma Program	Broadwing Bio	Pre-clinical	Active
MSC Exosomal Eye Serum	Vitti Labs	Pre-clinical	Active
TODDD™ Platform	Amorphex Therapeutics	Pre-clinical	Active